21 CFR 862.1093
§ 862.1093 Menopause test system.
United States · 21 CFR — Food and Drugs · Status: effective
Cite this
- Citation
- 21 CFR 862.1093, § 862.1093 Menopause test system, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/89053
- Permanent ID
ys:prov:89053@1- SHA-256
5a2033b1d9177dda08c6de1359c43098a8ef7249295bdd2fa3957cd835a86db3
The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.
Full text
(a) Identification. A menopause test system is an in vitro diagnostic device intended to measure hormones or other analytes in human clinical specimens as an aid in the determination of menopausal status in women.
(b) Classification. Class II (special controls). A menopause test system must comply with the following special controls:
(1) Design verification and validation must include the following:
(i) An appropriate traceability plan to minimize the risk of drift in the menopause test system results over time.
(ii) Detailed documentation of a clinical study to demonstrate clinical performance or, if appropriate, results from an equivalent sample set. This detailed documentation must include the following information:
(A) Results must demonstrate appropriate clinical performance relative to a well-accepted and appropriate comparator.
(B) Data must demonstrate accuracy of device output for each indicated specimen type throughout the device measuring range as appropriate for the intended use population.
(2) The labeling required under § 809.10 of this chapter must include the following:
(i) A statement in the indications for use that the device is intended to be used for the determination of menopausal status only in conjunction with other clinical and laboratory findings prior to any diagnostic or treatment decisions.
(ii) A limiting statement that the device is intended to be used for the determination of menopausal status only in conjunction with other clinical and laboratory findings prior to any diagnostic or treatment decisions.
(iii) A limiting statement appropriately describing the risks of false test results and that test results should not be relied upon in clinical decision making (e.g., to discontinue contraceptive use and/or to evaluate patients for the presence of endometrial cancer) without other clinical and laboratory findings.
Legislative history
This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.